MiR-218-XOR-ROS Pathway Regulates the Progression of Nonalcoholic Steatohepatitis

• Published in: Clinical laboratory (Heidelberg) Vol. 65; no. 12
• Main Authors: He, Junling, Zhang, Juanwen, Yu, Mosang, Huang, Yue, Dai, Yuying, Zheng, Ruoheng
• Format: Journal Article
• Language: English
• Published: Germany 01.01.2019
• Subjects: 3' Untranslated Regions - genetics; Animals; Base Sequence; Cell Line; Disease Models, Animal; Disease Progression; Gene Expression Regulation; HEK293 Cells; Humans; Male; Mice; Mice, Inbred BALB C; MicroRNAs - genetics; Non-alcoholic Fatty Liver Disease - genetics; Non-alcoholic Fatty Liver Disease - metabolism; Non-alcoholic Fatty Liver Disease - pathology; Reactive Oxygen Species - metabolism; RNA Interference; Sequence Homology, Nucleic Acid; Signal Transduction - genetics; Xanthine Dehydrogenase - genetics; Xanthine Dehydrogenase - metabolism
• ISSN: 1433-6510
• DOI: 10.7754/clin.lab.2019.190421

To investigate the role of the miR-218-xanthine oxidoreductase (XOR) pathway in the pathogenesis of nonalcoholic steatohepatitis (NASH) and to explore the potential downstream mechanisms involving oxidative stress and energy metabolism. The NASH animal model was established by feeding BALB/c mice with an MCD diet, while BRL-3A cells were cultured with a mixture of oleate and palmitate for 72 hours to mimic the steatosis and inflammation of NASH in vitro. The steatosis and inflammation levels were assessed by H-E/oil-red staining and serum/supernatant TG, ALT, and AST levels. The apoptosis degree was tested by the TUNEL/flow cytometry method both in animals and cultured cells. The XOR and miR-218 levels were detected by western blotting and qRT-PCR. Decreased miR-218 and increased XOR levels were identified in the NASH animal and cell models, while the regulation of miR-218 on XOR was also confirmed. NASH alleviation was achieved after miR-218 over-expression in vivo and in vitro, according to the declination of steatosis and inflammation-related markers. Although H2O2 and ATP levels were increased and decreased in NASH models, respectively, antagonizing miR-218 could significantly alleviate those changes. The miR-218-XOR pathway may provide a novel mechanism and treatment option for NASH.